Buscar resultados de ensayos clínicos
Neurofibroma - 181 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Condición:
|
Active, not recruiting |
Nombre del estudio: Medical Treatment of "High-Risk" Neurofibromas Condición: Neurofibromatosis 1 Fecha: 2009-01-16 Intervenciones:
|
Active, not recruiting |
Nombre del estudio: How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem Condición: Neurofibromatosis Type 1 Fecha: 2012-06-21 |
Completed |
Nombre del estudio: Quality of Friendships in Children With Neurofibromatosis Condición: Neurofibromatosis Fecha: 2007-07-26 Intervenciones: Behavioral: Questionnaire Questionnaire about the patient's relationship with their best friend. |
Suspended |
Nombre del estudio: Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas Condición:
|
Completed |
Nombre del estudio: R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas Condición:
Fecha: 2006-06-19 Intervenciones:
|
Completed |
Nombre del estudio: Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas Condición:
Fecha: 2004-01-13 Intervenciones: Drug: Pirfenidone Pirfenidone orally as capsules three times a day approximately every 8 hours for cycle |
Active, not recruiting |
Nombre del estudio: Study of PEG-Intron for Plexiform Neurofibromas Condición: Plexiform Neurofibroma Fecha: 2006-11-02 Intervenciones: Drug: PEG-Intron |
Recruiting |
Nombre del estudio: Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas Condición: Plexiform Neurofibromas Fecha: 2014-06-25 Intervenciones: Drug: Imatinib Mesylate oral administration Other Na |
Terminated |
Nombre del estudio: Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) Condición: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1 Fecha: 2011-05-27 Intervenciones: Drug: Everolimus (RAD001) oral daily dosing of tablet starting with 2.5 mg |